Infections by multidrug-resistant bacteria impose a serious encumbrance worldwide on society 61 and economy and account for increasing global morbidity and mortality (1). Variable responses 62 to antibiotics from bacterial cells within the same population, known as heteroresistance, is a 63 poorly characterized phenomenon that further complicates the study of antibiotic resistance and 64 its clinical relevance is uncertain. Heterogeneous antibiotic resistance was first described in 1947 65 for the Gram-negative bacterium Haemophilus influenzae (2), and almost 20 years later for 66
Gram-positive staphylococci (3), but the first reported use of the term 'heteroresistance' occurred 67 in 1970 (4). Heterogeneous resistance, population-wide variation of resistance, and heterogeneity 68 of response to antibiotics are also used to describe this phenomenon. The Clinical and 69 Laboratory Standards Institute (CLSI), the British Society of Antimicrobial Chemotherapy 70 (BSAC), and other international bodies develop clinical laboratory standards and 71 recommendations for practices concerning antimicrobial resistance (5). Therefore, antimicrobial 72 susceptibility testing methods such as MIC and disc-diffusion techniques, and standard criteria to 73 define isolates as susceptible, resistant or intermediately resistant to any antibiotic are generally 74 agreed upon worldwide. In contrast, heteroresistance is poorly characterized and consensus-75 based standards to define it are lacking. 76
In the literature, the term 'heteroresistance' has been indiscriminately applied to describe not 77 only population-wide variation in antibiotic resistance but also other observations, and methods 78 to determine heteroresistance vary significantly among laboratories. Confusion regarding this 79 phenomenon precludes establishing its clinical significance and implementing proper therapeutic 80 interventions and guidelines. Therefore in this review, we critically assess the published 81 literature on heteroresistance, expose contradictions and variations in its definition, and 82 recommend an operational definition and uniform criteria to assess heteroresistant bacteria. 83
84

MULTIPLE DEFINITIONS OF HETERORESISTANCE 85
Heteroresistance means population-wide, variable response to antibiotics (6). Several reports 86 including the earliest studies describing the phenomenon applied this definition without 87 specifying a particular antibiotic concentration range (3, 4, 7, 8) . In contrast, concentration 88 ranges were indicated for heteroresistance in Acinetobacter baumannii where subpopulations 89 grew in 3 to 10 µg/ml colistin while the culture's MIC ranged from 0.25 to 2 µg/ml (9). Others 90 described heteroresistance when a subset of the microbial population was resistant to an 91
Population analysis profiling (PAP) 138
The PAP method is considered the gold standard for determining heteroresistance. In this 139 method, the bacterial population is subjected to a gradient of antibiotic concentrations (either on 140 plates or in liquid medium) and bacterial growth at each of these concentrations is quantified. 141
The PAP is typically performed using the format of standard MIC determination with 2-fold 142 antibiotic increments and by spread-plate techniques for CFU counting (3, 4, 6, 8, 14, 16, 18, 19, 143 25-41) . Counting CFU by dropping smaller aliquots was as efficient as spread-plate (6, 42) . 144
Turbidimetric PAP assays are also performed using 2-fold antibiotic increments (6, 43), and 145 antibiotic increments wider than 2-fold steps (2, 44). 146
Recently, heteroresistance was considered if the antibiotic concentration exhibiting the 147 highest inhibitory effects was at least 8-fold higher than the highest non-inhibitory concentration 148 (6), which allows comparisons of the isolate's behaviour against different antibiotics. However, 149 most studies lacked criteria to define homogeneous vs. heterogeneous resistance. Lack of a 150 standardized method to perform PAP, in particular the selection of antibiotic concentration 151 increments led to confounding observations. For example, several studies investigated the 152 response to glycopeptide antibiotics using PAP assays with narrow increments in antibiotic 153 concentrations, such as 1 µg/ml steps (9, 13, 45-65) and even as low as 0.1 µg/ml steps (66). In 154 these cases, a homogeneous strain could be inaccurately considered heteroresistant, and 155 sometimes the same strain appeared as homogenous in one curve and heterogeneous in another 156 (12) . 157 A modified PAP assay comparing the area under the curve (PAP-AUC) of a given strain to 158 that of a reference heteroresistant strain was used to determine S. aureus heteroresistance to 159 vancomycin (67-81). The PAP-AUC ratios between test and control strain of <0.9, 0.9 to 1. 3 contains vancomycin and the other teicoplanin. As with PAP, lack of standard guidelines 177 hampers detection of heteroresistance using Etest and disc diffusion assays. An obvious 178 indication of heteroresistance is the appearance of distinct colonies growing within the clear zone 179 of inhibition in the disc diffusion or Etest assays. However, many reports set cut-off 180 concentrations or inhibition zone diameters to decide on the heterogeneity of the response of the 181 bacterial population to antibiotics as discussed before, but such cut-off values cannot sufficiently 182 describe the population-wide behaviour. 
HETERORESISTANCE IN DIFFERENT BACTERIAL SPECIES 199
Heteroresistance denotes the presence of subpopulations of bacterial cells in the same culture 200 with higher levels of antibiotic resistance. Individual subpopulations of more resistant bacteria 201 were often isolated, but their stability differed. Typically, after five to ten serial passages in 202 antibiotic-free medium some highly resistant subpopulations reverted to the heterogeneous 203 resistance phenotype displayed by their original population (3, 30, 40), whereas others retained 204 their high-level resistance (6, 28). Most of the reported incidences of heteroresistance involve 205 bactericidal antibiotics including β-lactams, glycopeptides, antimicrobial peptides, 206 fluoroquinolones, aminoglycosides, and the nitroimidazole antibiotic metronidazole that acts on 207 anaerobic bacteria (Tables 1 and 2). No systematic comparisons of the response of  208   heteroresistant bacteria to bacteriostatic versus bactericidal antibiotics have been reported, except  209 for one study in Burkholderia cenocepacia (6) showing heteroresistance to different classes of 210 bactericidal antibiotics and homogenous responses to bacteriostatic antibiotics. Two studies 211 reported incidences of heteroresistance against bacteriostatic antibiotics. One of them involved S. 212 aureus strains heteroresistant to fusidic acid (45), but PAP was performed using a narrow range 213 of antibiotic concentrations in small increments. The other study reported Bordetella pertussis 214 strains being heteroresistant to erythromycin (88), which appear as discrete colonies in the clear 215 zones of inhibition after 7 days of incubation in Etest and disc diffusion assays. 216
Heteroresistance in Gram-positive bacteria was reported for S. aureus, as well as for other 217
Staphylococci, Enterococci and Clostridium difficile. The earliest reports of heteroresistance in S. 218 aureus were on the response to methicillin (3, 4), but this extended to other β-lactams, which 219 accounted for the majority of research on heteroresistance until late 1990s (Table 1) . 220
Heteroresistance to vancomycin and other glycopeptides was first detected in Japanese 221 vancomycin-resistant S. aureus (13). This also initiated a trend of PAP testing with a narrow 222 range of antibiotic concentrations in very small increments, which were used to determine the 223 clinical relevance and spread of vancomycin resistance in MRSA infections. However, 224 controversial findings, originating from similar time range and geographical distribution, 225 indicated that "heterogeneity" in response to vancomycin is common among S. aureus strains 226 (47, 50, 61, 63, 70, 79, 95) . Others reported that heteroresistance to vancomycin was not 227 prevalent (51, 64, 72, 73, 80, 81, 102, 106). These studies promoted the assessment of 228 heteroresistance in clinical laboratories as a standard procedure, but the results were conflicting 229 since different criteria to define heteroresistance were adopted and improper methods to detect 230 heterogeneity were mostly used (discussed above under 'Measuring Heteroresistance'). 231
Fewer reports described heteroresistance in Gram-negative bacteria. Table 2 summarizes Heteroresistance may also be misinterpreted when only a single colony, picked from primary 420 bacterial populations isolated from patients, is analyzed for its susceptibility to antibiotics (86). 421
Heteroresistance was relevant in recurrent infections (46, 71), chronic infections (78), and 422 infections with increased mortality rates (64, 77, 150, 151). Underlying mechanisms for these 423 therapeutic failures could be antibiotic selection for the more resistant cells within the bacterial 424 population and chemical communication of resistance, as described in more detail below. 425 426
Selection for the more resistant cells in the population 427
Therapeutic dosing of antibiotics without considering the highly resistant subpopulations of a 428 heteroresistant isolate would select for the more resistant subpopulations. This is particularly the 429 case when the majority of the population is sensitive to antibiotics while only a small subset, 430 undetectable through criteria set for traditional in vitro antibiotic susceptibility testing, displays 431 resistance above the clinical breakpoint (Fig. 1) . In these situations, antibiotic therapy would lead 432 to eradication of the more sensitive members of the bacterial population and their replacement by 433 the more resistant cells. 
CONCLUSIONS AND RECOMMENDATIONS 480
Despite being recognized since 1947, heteroresistance is often used indiscriminately to describe 481 observations unrelated to population-wide responses to antibiotics. Lack of standard test formats 482 and global guidelines for determining heteroresistance contribute to disagreements between 483 outcomes of different methods and diverse results from different laboratories (69, 74, 75). Since 484 heteroresistance could have serious implications in antimicrobial therapy, a standard operational 485 definition and methods to assess its clinical importance are essential. 486
We recommend defining heteroresistance as the population-wide variation of antibiotic 487 resistance, where different subpopulations within an isolate exhibit varying susceptibilities to a 488 particular antimicrobial agent. Concerning methods, PAP remains the gold standard for detecting 489 heteroresistance by CFU counts. Turbidimetric PAP is also an acceptable alternative if antibiotic 490 concentration increments are set at 2-fold; however, monitoring bacterial growth at time points 491 earlier than 24 h (and after reaching the late log-phase/early stationary phase) may be advisable 492 to watch for outgrowth of the more resistant subpopulation. Therefore, an isolate can be 493 considered heteroresistant when the lowest antibiotic concentration giving maximum growth 494 inhibition is greater than 8-fold higher than the highest non-inhibitory concentration. A 8-fold 495 difference could be regarded as intermediate heteroresistance, while a smaller difference would 496 denote homogenous response to the antibiotic. In homogeneous cultures, the entire population is 497 usually inhibited over a narrow increment of antibiotic in standard MIC broth or agar dilution 498 assay, with cases of intermediate growth before reaching maximal inhibition at only one 499 antibiotic concentration increment above the highest non-inhibitory concentration. This general 500 observation of homogeneous response to antibiotics has been documented by PAP assays in our 501 recent study (6). Since 2-fold fluctuations in antibiotic sensitivity could normally occur, further 502 increase in the transition from no inhibition to full inhibition by 2-fold relative to the 503 homogeneous response was considered intermediate heteroresistance; greater differences (>8-504 fold) indicated heteroresistance as previously shown (6). This is similar to results observed in 505 previous reports but with more standardization; for example, the concentration inhibiting the 506 entire population in PAP assays was 8-fold higher than MIC values (which cannot detect the 507 more resistant minority) as opposed to homogeneous bacteria where it is the same concentration 508 or just 2-fold higher (41). Disc diffusion or Etest assays, where growth of discrete colonies 509 within the clear zone of inhibition indicates heteroresistance, could be an alternative to PAP. 510
These discrete colonies represent subpopulations growing at concentrations that are inhibitory to 511 the rest of the bacterial population suggesting population-wide variation in resistance. Antibiotic 512 diffusion methods may therefore speed up screening of clinical isolates, but cannot replace PAP 513 assays. In the absence of specific recommendations to address heteroresistance from agencies 514 concerned with antibiotic resistance such as CLSI, BSAC and others, we propose a workflow 515 scheme and interpretation criteria based on standard antibiotic sensitivity testing recommended 516 by the same agencies (Fig. 2) . This scheme includes modifications in the read-out and existing 517 standard assays for detection of population-wide variation in antibiotic resistance (Fig. 2) . 518
Having worldwide standard criteria to define and assess heteroresistance will facilitate assessing 519 its prevalence, clinical relevance, and impact on healthcare. Consequently, effective therapeutic 520 strategies should be explored to counteract heteroresistance, which may include testing 521 synergistic combinations of antibiotics (159) and using antibiotic adjuvants inhibiting key 522 pathways involved in antibiotic resistance in conjunction with frontline antibiotics (6). A 523 standard definition of heteroresistance would also help elucidate its nature by determining 524 whether common mechanisms exist among different bacteria and against different antibiotic 525 classes, and finding new targets for its disruption. 526
We urge global organizations concerned with antimicrobial resistance to advocate for 527 harmonized recommendations and coordinate general consensus concerning heteroresistance. 528
We believe this is of utmost importance especially in clinical practice where currently thousands 529 of clinical isolates are screened for heteroresistance, but with non-standardized methods that 530 differ among laboratories, precluding obtaining a global picture of this problem. We anticipate 531 that accurate and standardized detection of heteroresistance will translate to superior therapeutic 532 outcomes based on improved identification of heteroresistant bacteria and optimized strategies to 533 eradicate them. 534 concern of increasing clinical significance? Clin Microbiol Infect 14:101-104. 567
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Lo-Ten-Foe JR, Subpopulations (<0.1% from 10 8 -10 9 CFU/ml) grew in the presence of colistin 3 to 10 µg/ml while the MIC of entire populations ranged from 0.25-2 µg/ml. Warned that recommended dosing is suboptimal for heteroresistant strains (9)
P. aeruginosa Imipenem; Meropenem
Disc diffusion (colonies in inhibition zone); PAP by CFU: (narrow increments and low initial inoculum)
Subpopulations growing at high concentration at frequencies 6.9 x 10 -5 -1.1 x 10 -7 , suggest that these cells might not be detected by standard agar dilution MIC assay 
